📄 Cross-examination of Dr. John Gerdes (part 8) — Friday, August 4, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\4\CROSS-EXAMINATION-OF-DR-JOHN-G.DOC
TRIAL
▲ Day 129 of 167

Cross-examination of Dr. John Gerdes (part 8)

Witness: Dr. John Gerdes
Examiner: George Clarke
Called by: Defense • Date: Friday, August 4, 1995 • Utterances: 304
Prosecutor George Clarke cross-examined defense DNA expert Dr. John Gerdes, attacking the reliability of his contamination charts by establishing that they included 1.1 and 1.3 alleles that may reflect cross-hybridization rather than true contamination, potentially overstating LAPD lab contamination rates. Clarke then used a newly introduced photograph (People's 568) of a January 1994 LAPD run showing gross contamination to make the opposite point — that the LAPD's quality controls successfully detected and flagged that contamination, undermining Gerdes' overall critique of the lab.
1 MR. CLARKE:

Dr. Gerdes, you have conceded that if in fact a signal such as in the photographs that have been shown to this jury are the result of cross-hybridization, then they are not the result of contamination, correct?

2 DR. GERDES:

Correct.

3 MR. CLARKE:

As far as the creation of your chart and in fact there were a number of charts shown to the jury that discussed and had bars or graphs of contamination, do you recall those?

4 DR. GERDES:

I do.

5 MR. CLARKE:

In those instances in which, for instance, there is cross-hybridization instead of contamination, those charts are biased as far as the presence of contamination in the LAPD laboratory, correct?

6 DR. GERDES:

I think we tried to explain what the degree of bias would be and so for instance on the 1.1, that was 7.6 percent of the strips, and on the 1.3, that was 25 percent, so if it is biased we attempted to explain the bias.

7 MR. CLARKE:

In other words, the way the charts are written assumes that what might be cross-contamination is contamination?

8 MR. SCHECK:

Objection.

9 THE COURT:

Argumentative. Sustained.

10 MR. CLARKE:

Do those charts reflect then and include in those graphs of contamination incidents which may are the result of cross-hybridization?

11 DR. GERDES:

Only for the specific case of the 1.1 allele and the 1.3 allele.

12 MR. CLARKE:

Is it then the case that what may be a graph that you show 100 percent of runs contaminated, that if in fact the 1.3 and 1.1 alleles are present, then those charts overstate the contamination?

13 DR. GERDES:

I don't believe so, because the reason I analyzed it in that manner was to look at more than one strip to attempt to find the confirmation.

14 MR. CLARKE:

Does that mean, Dr. Gerdes, when you describe the 25 percent and the 7.6 percent, that your charts may overstate the contamination at the Los Angeles Police Department by over 32 percent?

15 MR. SCHECK:

Objection, vague question.

16 THE COURT:

Overruled.

17 DR. GERDES:

Remember, those are the percentage of those specific alleles and those are only two of the six alleles, so in terms of--if I could look at my notes?

18 MR. CLARKE:

Do you need to look at your notes for some answer for a portion of this answer?

19 DR. GERDES:

For an example, yes. If we sum the total 1.1 plus 1.3 that could possibly be DX or cross-contamination, that could be 16.5 percent of those alleles.

20 MR. CLARKE:

Dr. Gerdes, what I'm asking is when you have, say, the month of May, 1994, and you show--and I'm not trying to give an exact number for the month of May. Let's just assume you have a number, whether it is forty percent, fifty percent or sixty percent, you have a bar graph that approximates that percentage, correct?

21 MR. SCHECK:

Objection, vague as to which chart, which bar graph.

22 THE COURT:

Sustained.

23 MR. CLARKE:

With regard to these graphs there is one that describes run contamination and describes contamination for May, June and July, correct?

24 DR. GERDES:

Yes.

25 MR. CLARKE:

With regard to that particular graph--and let's assume for May there is a certain percentage of strip contamination whatever that is, all right?

26 DR. GERDES:

Yes.

27 MR. CLARKE:

That figure, whatever that percentage is, does that include these 1.1 and 1.3 instances?

28 MR. SCHECK:

Misstates the chart.

29 THE COURT:

Overruled.

30 MR. SCHECK:

The chart speaks for itself.

31 THE COURT:

Overruled.

32 DR. GERDES:

Are you talking about the strip chart or the run chart?

33 MR. CLARKE:

I'm talking about the chart that has both.

34 DR. GERDES:

On the strip chart those would be included. On the run chart the entire date would be evaluated with one sample versus the other, so I could confirm whether or not that was contamination or not.

35 MR. CLARKE:

Dr. Gerdes, I'm not sure you can see that from there. Perhaps if you would step down.

36 (Witness complies.)
37 THE COURT:

This is 1297 if I recollect.

38 MR. CLARKE:

Yes. Thank you, your Honor.

39 MR. CLARKE:

Dr. Gerdes, with regard to this particular exhibit, is this the chart that I just questioned you about as far as demonstrating for May, June and July your opinion of contamination levels by both runs and strips?

40 DR. GERDES:

Yes, it is.

41 THE COURT:

All right, doctor. Would you take a half step back. You are shielding the court reporter. Thank you.

42 DR. GERDES:

I'm sorry.

43 MR. CLARKE:

If I could, Dr. Gerdes, let's take June where there is a 33 percent indication of strips.

44 DR. GERDES:

Excuse me. You are pointing to May.

45 MR. CLARKE:

I'm sorry, referring to May where there appears to be a green block that contains strip contamination or artifacts; is that correct?

46 DR. GERDES:

That's correct.

47 MR. CLARKE:

Does that 33 percent include the 1.1 alleles?

48 DR. GERDES:

At that point it does.

49 MR. CLARKE:

Does it include the 1.3 allele?

50 DR. GERDES:

Yes.

51 MR. CLARKE:

The 1.1 alleles can be the result of DX contamination or artifacts?

52 DR. GERDES:

That's correct.

53 MR. CLARKE:

The 1.3 can be the result of cross-hybridization under your testimony; is that correct?

54 DR. GERDES:

That's true.

55 MR. CLARKE:

33 percent includes both of those?

56 DR. GERDES:

It does.

57 MR. CLARKE:

In fact, if those are not from contamination, those overstate the percentage of contamination, don't they?

58 DR. GERDES:

They would by less than 16 percent overall.

59 MR. CLARKE:

So it is your view that it only overstates it to a certain extent, but the chart is still correct?

60 DR. GERDES:

If I can explain? May I explain, your Honor.

61 MR. CLARKE:

Well, the question is--

62 MR. SCHECK:

May the witness explain?

63 THE COURT:

He answered the question. He can explain his answers on redirect examination.

64 MR. CLARKE:

Dr. Gerdes, my question to you is in your opinion does the 33 percent then overstate the occurrence of contamination if in fact those 1.1 and 1.3 alleles are not from contamination?

65 DR. GERDES:

With regards to that specific strip, this specific bar, that might be overstated. That is why I did the analysis the way I did, to look to the next one over which is the run contamination, so if we can look at May 12th I can explain how I confirm whether or not these are contaminated.

66 MR. CLARKE:

Incidentally, these percentages and your inclusion of those 1.3 and 1.1's, was that also true of the 31 percent in June?

67 DR. GERDES:

That is why it is labeled "Strip contamination and/or artifact." It is clearly labeled as that. That is what it is.

68 MR. CLARKE:

Objection, nonresponsive, your Honor.

69 THE COURT:

Sustained. Ask the question again.

70 MR. CLARKE:

Dr. Gerdes, when you calculated 31 percent for the month of June, did that include the 1.1 and 1.3 alleles that may not be from contamination?

71 DR. GERDES:

Yes.

72 MR. CLARKE:

The 17 percent reported in July, did those also include the 1.1 and 1.3 alleles that may not be contamination at all?

73 DR. GERDES:

Yes.

74 MR. CLARKE:

Thank you, doctor. You may resume the stand.

75 (Witness complies.)
76 MR. CLARKE:

Your Honor, I have a photograph--I think the projector is back--I would ask to be mark as People's 568.

77 THE COURT:

568.

78 (Peo's 568 for id = photograph)
79 MR. CLARKE:

Which I have previously shown to counsel.

80 THE COURT:

Proceed.

81 MR. CLARKE:

Dr. Gerdes, showing you one more photograph, does that appear to be another hybridization record photograph that you reviewed as part of your review of the strips at the LAPD?

82 DR. GERDES:

If I could just check it?

83 MR. CLARKE:

Sure.

84 DR. GERDES:

(Witness complies.) Yes, it does.

85 MR. CLARKE:

And that particular run was conducted--well, that reflects a certain hybridization record number?

86 DR. GERDES:

Hybridization 101.

87 MR. CLARKE:

And do you have a Xerox copy of what is contained?

88 DR. GERDES:

No, I have a photo.

89 MR. CLARKE:

A photo as well?

90 DR. GERDES:

Yes.

91 MR. CLARKE:

Your Honor, with the Court's permission I would like to display this photo.

92 (Brief pause.)
93 MR. CLARKE:

Just for purposes of identifying this particular photograph, Dr. Gerdes, what date was this run conducted?

94 DR. GERDES:

1/14/94.

95 MR. CLARKE:

January of `94?

96 DR. GERDES:

Correct.

97 MR. CLARKE:

The analyst was whom?

98 DR. GERDES:

Erin Riley.

99 MR. CLARKE:

And the confirming analyst was Collin Yamauchi?

100 DR. GERDES:

Yes.

101 MR. CLARKE:

This was one of the strips you looked at as part of your review of the LAPD DNA work?

102 DR. GERDES:

There series of strips, yes.

103 MR. CLARKE:

What was contained on this series of strips?

104 DR. GERDES:

The first five items are actually evidence items, then there is a standard no. 5, a negative control, and then another evidence item.

105 MR. CLARKE:

Okay. When you say the first five items were case work, that is case work but not related to this case, correct?

106 DR. GERDES:

That's correct.

107 MR. CLARKE:

In other words, this is an example of your review of their work that included actually other criminal cases but not this one?

108 DR. GERDES:

That's correct.

109 MR. CLARKE:

Is that why it has a number that appears to be 93 dash and a series of numbers?

110 DR. GERDES:

That is a code number for a different case, yes.

111 MR. CLARKE:

As part of your review that type of number tells us it is case work, correct?

112 DR. GERDES:

Correct.

113 MR. CLARKE:

Instead of like CTS or known reference sample and so forth?

114 DR. GERDES:

Correct.

115 MR. CLARKE:

Now, in this particular instance the analyst--and there were eight strips run in this particular instance?

116 DR. GERDES:

On this particular page, yes.

117 MR. CLARKE:

Now, if we could focus in on the written results column up to the far right, that column and the first five strips, I'm sorry, are evidence samples again; is that correct?

118 DR. GERDES:

That's correct.

119 MR. CLARKE:

The next sample, which is in what would it be no. 6, is labeled standard no. 5?

120 DR. GERDES:

Correct.

121 MR. CLARKE:

That would be a known blood from a known person?

122 DR. GERDES:

Correct.

123 MR. CLARKE:

Or positive control?

124 DR. GERDES:

It is a positive control, yes.

125 MR. CLARKE:

Below that is labeled "Neg." control?

126 DR. GERDES:

Yes.

127 MR. CLARKE:

And is that what is referred to as a reagent blank or cloth control?

128 DR. GERDES:

That's correct.

129 MR. CLARKE:

And then lastly, is there another case work sample?

130 DR. GERDES:

That's correct.

131 MR. CLARKE:

Which looks like it has a number beginning with 89?

132 DR. GERDES:

Correct.

133 MR. CLARKE:

Does that indicate the year of the case?

134 DR. GERDES:

I believe so.

135 MR. CLARKE:

So is it the case then that the Los Angeles Police Department DNA laboratory would actually look at cases that were, for instance, several years old as part of their DNA typing?

136 DR. GERDES:

Apparently that is true.

137 MR. CLARKE:

Now, over to the right where all the results are written, there appear to be many different alleles noted for all the samples, correct?

138 DR. GERDES:

That's true.

139 MR. CLARKE:

As part of the review of a run an analyst wants to look at the negative control, for instance; is that right?

140 DR. GERDES:

Correct.

141 MR. CLARKE:

And is that the type of control that an analyst would look at first?

142 DR. GERDES:

Generally, yes.

143 MR. CLARKE:

Or if not first, very close to first?

144 DR. GERDES:

Yes.

145 MR. CLARKE:

Because that control is very important in determining whether or not a PCR run is contaminated?

146 DR. GERDES:

Correct.

147 MR. CLARKE:

Now, in this particular instance the analyst noted, as far as the negative control, the presence of what looked like four alleles, correct?

148 DR. GERDES:

Yes. On the negative control, which again should have no DNA, there is a 1.2, 2, a 4 and a 1.1.

149 MR. CLARKE:

Now, if we could move up to the appropriate strip where the actual dots are noted, that would be the second strip from the bottom, Dr. Gerdes?

150 DR. GERDES:

Correct.

151 (Discussion held off the record between the Deputy District Attorneys.)
152 MR. CLARKE:

We will see if we can place an arrow, just so it is clear, which strip we are referring to. That would be second from the bottom, Dr. Gerdes?

153 DR. GERDES:

That's correct.

154 MR. CLARKE:

Is the arrow currently pointing to that particular strip right there?

155 DR. GERDES:

Yes.

156 MR. CLARKE:

Now, that negative control should show no dots in any of the probes, correct?

157 DR. GERDES:

It should be totally clean. There should be nothing there.

KEY QUOTE
158 MR. CLARKE:

And we are seeing a 1 dot?

159 DR. GERDES:

Yes.

160 MR. CLARKE:

A 2 dot?

161 DR. GERDES:

Yes.

162 MR. CLARKE:

A 4 dot?

163 DR. GERDES:

Yes.

164 MR. CLARKE:

Is there a C dot?

165 DR. GERDES:

Yes, on my photo there is.

166 MR. CLARKE:

But faint, would that be a fair description?

167 DR. GERDES:

Yes.

168 MR. CLARKE:

Is there a 1.1 dot?

169 DR. GERDES:

Yes.

170 MR. CLARKE:

Similarly faint?

171 DR. GERDES:

About the same as C.

172 MR. CLARKE:

Now, the 1.2, 1.3, 4 dot, without getting into its interpretation in this particular sample, is showing a clean reaction, correct?

173 DR. GERDES:

It is.

174 MR. CLARKE:

Is there a reaction in the 1.3 dot?

175 DR. GERDES:

No.

176 MR. CLARKE:

And lastly, the all but 1.3, that is going to basically show a reaction if any allele is present other than the 1.3, right?

177 DR. GERDES:

Correct.

178 MR. CLARKE:

So that is another sample that you use to interpret the results?

179 DR. GERDES:

Correct.

180 MR. CLARKE:

Now, if we could go back to the actual result section, and just first before we do that, then this is a signal to an analyst that there is a problem with this run, correct?

181 DR. GERDES:

Yes.

182 MR. CLARKE:

It is a clear signal, isn't it?

183 DR. GERDES:

This is gross contamination.

KEY QUOTE
184 MR. CLARKE:

If we could return to the results column in the written portion and go to the far right, and that is fine, as far as zoom in or zoom out. There is the appearance of many alleles in each of these samples, correct?

185 DR. GERDES:

That's correct.

186 MR. CLARKE:

It is fairly easy to determine that there is contamination in this run, correct?

187 DR. GERDES:

Yes.

188 MR. CLARKE:

And in fact the analyst noted that contamination, correct?

189 DR. GERDES:

They did.

190 (Discussion held off the record between the Deputy District Attorneys.)
191 MR. CLARKE:

It is correct that the control worked in this instance revealing contamination, correct, Dr. Gerdes?

KEY QUOTE
192 DR. GERDES:

In this particular case, yes.

193 MR. CLARKE:

And in fact they clearly were?

194 DR. GERDES:

In this particular case, yes.

195 MR. CLARKE:

All right. Could I have just a moment, your Honor?

196 (Discussion held off the record between the Deputy District Attorneys.)
197 MR. CLARKE:

Dr. Gerdes, as far as the materials you received in this case, you were provided, I believe you described materials relating to DNA testing by LAPD?

198 DR. GERDES:

Yes.

199 MR. CLARKE:

Cellmark?

200 DR. GERDES:

Yes.

201 MR. CLARKE:

And the Department of Justice?

202 DR. GERDES:

Yes.

203 MR. CLARKE:

And did you review all of those materials?

204 DR. GERDES:

I did.

205 MR. CLARKE:

You were also provided, and in particular, with reports from each of those laboratories?

206 DR. GERDES:

That's correct.

207 MR. CLARKE:

I'm referring to DNA work as well--as far as your reports?

208 DR. GERDES:

Specifically, yes.

209 MR. CLARKE:

Were you provided any of the serological reports, that is, the results obtained by conventional serology?

210 DR. GERDES:

No.

211 MR. CLARKE:

Were you provided bench notes relating to the DNA work?

212 DR. GERDES:

Yes.

213 MR. CLARKE:

Were you provided all of the x-rays or autoradiographs?

214 DR. GERDES:

The majority, yes.

215 MR. CLARKE:

Are there some you are aware of that you were not provided?

216 DR. GERDES:

Yes.

217 MR. CLARKE:

What about the D1S80 films? They are somewhat like autoradiographs in appearance, correct?

218 DR. GERDES:

Yes.

219 MR. CLARKE:

Were you provided those?

220 DR. GERDES:

Yes.

221 MR. CLARKE:

Were you provided photographs, for instance, of typing strips, and I'm referring to the case work itself in this case?

222 DR. GERDES:

Yes.

223 MR. CLARKE:

Were you provided photographs of product gels as they are called where there is an evaluation of the presence of DNA and how much?

224 DR. GERDES:

Yes.

225 MR. CLARKE:

Were you provided photographs--well, or other--let me rephrase that. Were you provided x-rays or copies of those x-rays of what are called slot-blots that are another method of determining approximately how much DNA is present?

226 DR. GERDES:

I have not seen the original slot-blots from either the DOJ or from Cellmark. As far as the autorad itself, I have seen Xerox copies.

227 MR. CLARKE:

So you haven't seen any of the slot-blots that quantitate?

228 DR. GERDES:

I have seen the recorded results. I have not seen that the autorad that goes with that, other than a copy.

229 MR. CLARKE:

Does Cellmark record the actual amounts from a slot-blot or is the x-ray the data from which they interpret it and don't note it in a written document?

230 DR. GERDES:

They don't note it.

231 MR. CLARKE:

So therefore it is correct that you have seen no reports or photographs detailing the amount of DNA that Cellmark determines from a sample?

232 DR. GERDES:

Not directly from Cellmark.

233 MR. CLARKE:

Have you received it from some other source?

234 DR. GERDES:

From Department of Justice.

235 MR. CLARKE:

Well, I'm referring to Cellmark?

236 DR. GERDES:

The same item.

237 MR. CLARKE:

I'm sorry, maybe I didn't make it clear.

238 DR. GERDES:

It was related to me through--I believe it was related to me through, umm--umm, discussions with testimony by Robin Cotton and I read those testimonies in which she specifically stated what the DNA amounts were on the items in question.

239 MR. CLARKE:

Were you provided materials about proficiency testing by all three laboratories?

240 DR. GERDES:

Yes.

241 MR. CLARKE:

And did you review all of that material?

242 DR. GERDES:

Yes.

243 MR. CLARKE:

Were you provided--and you've already described receiving and reviewing each of the validation DQ-Alpha strips at the Los Angeles Police Department. Did you review validation materials from the other two laboratories as well?

244 DR. GERDES:

I did.

245 MR. CLARKE:

Did you review the accreditation materials from Cellmark Diagnostics, that is, accreditation by the American Society of Crime Laboratory Directors?

246 DR. GERDES:

I have seen documents related to that, yes.

247 MR. CLARKE:

And were those documents specific to Cellmark Diagnostics?

248 DR. GERDES:

Yes.

249 MR. CLARKE:

Were there also similar material from the Department of Justice that you received and reviewed?

250 DR. GERDES:

I may have. I don't recall offhand seeing the specific document on that.

251 MR. CLARKE:

You have described reading some of the transcripts in this case, that is transcripts of testimony?

252 DR. GERDES:

Umm, I read the transcripts of individuals that related to DNA. I haven't read the transcripts of the entire case.

253 MR. CLARKE:

What witness' testimony have you read the transcripts of?

254 DR. GERDES:

Mazzola, Fung, Collin Yamauchi, Gary Sims, Renee Montgomery, Robin Cotton and I may have forgotten somebody, but basically anyone who dealt with either sample collection or DNA analysis.

255 MR. CLARKE:

That is a lot of transcripts, isn't it?

256 DR. GERDES:

It is.

257 MR. CLARKE:

Can you approximate for us how many hours you have spent just reading those transcripts or days or weeks, whatever is easier?

258 DR. GERDES:

Perhaps, you know, all total a week or two time.

259 MR. CLARKE:

One or two weeks to read the transcripts of each of those witnesses--all of those witnesses?

260 DR. GERDES:

Perhaps a week or two, yes.

261 MR. CLARKE:

Have you received any videotapes for your review?

262 DR. GERDES:

I have seen clips of videotapes, but I have never received them myself.

263 MR. CLARKE:

By "Clips" do you mean on television?

264 DR. GERDES:

Yes, on TV or, you know, played during the course of the trial.

265 MR. CLARKE:

As opposed to a videotape that you received and watched--

266 DR. GERDES:

I did not receive any videotapes.

267 MR. CLARKE:

Are there any other materials that you were provided with respect to this case?

268 DR. GERDES:

I believe we covered most of them.

269 MR. CLARKE:

You reviewed all of those materials, correct?

270 DR. GERDES:

Yes.

271 MR. CLARKE:

You made notes as a portion of your review?

272 DR. GERDES:

Yes.

273 MR. CLARKE:

You compiled a chart?

274 DR. GERDES:

Yes.

275 MR. CLARKE:

As far as your notes, how many notes--I mean can you state it in terms of pages how many notes you took, and I'm setting aside the chart with the raw data on it?

276 DR. GERDES:

Most of my notes were taken during the--I had one or two pages of lab--of notes on the lab site visits. I had perhaps a page or two involved in analyzing or looking at the strips for each particular area as far as just summarizing and that is all.

277 MR. CLARKE:

You have used the term "Site visit." Site visit has a special meaning in science, doesn't it?

278 DR. GERDES:

Well, it can.

279 MR. CLARKE:

What does it mean?

280 DR. GERDES:

Well, it--that is what you would call, for instance, if you were applying for a grant from the NIH and they requested a site visit, that would simply mean they wanted to come and look at your lab and inspect it.

281 MR. CLARKE:

That is a fairly formalized procedure, isn't it, for an inspection of your laboratory?

282 DR. GERDES:

Yes.

283 MR. CLARKE:

And in fact that inspection can have serious consequences to the laboratory; is that correct?

284 DR. GERDES:

That's correct.

285 MR. CLARKE:

A site visit is performed by authorized personnel, for instance, from a government agency, right?

286 DR. GERDES:

Correct.

287 MR. CLARKE:

Is it your view that your visits to each of the laboratories in this case were site visits?

288 DR. GERDES:

Perhaps it is a misnomer. I visited the laboratory. I am under no authority of any accrediting agency or anything like that.

289 MR. CLARKE:

When you reviewed the results and all of this raw data, did there ever come a question in your mind about how a result was interpreted or how a procedure was in fact undertaken by the analyst?

290 DR. GERDES:

I was provided with all of the protocols from the laboratories, so I had access to those materials.

291 MR. CLARKE:

Well, what I'm asking, is other than from the material, even if you reviewed all of those, were there any questions in your mind about how an analyst performed a particular task? Did that ever happen?

292 DR. GERDES:

Based on all the information I have, all of those things we just discussed, no.

293 MR. CLARKE:

So from your review of the materials you had no questions whatsoever?

294 DR. GERDES:

No, and remember, I have seen these--with the specific example of Cellmark and DOJ, I have done other cases involved in those particular laboratories, so I'm familiar with they are protocols and procedures.

295 MR. CLARKE:

And you felt that that was a sufficient familiarity so that you could review all of these materials from all of these samples and have no questions of the analysts whatsoever?

296 DR. GERDES:

If you've ever seen Gary Sims' notes, they are extremely detailed. All you have to do is read the notes.

KEY QUOTE
297 MR. CLARKE:

And that was in your view sufficient for you to be able to render all of your conclusions thus far in this case?

298 DR. GERDES:

Based--yes.

299 (Discussion held off the record between the Deputy District Attorneys.)
300 MR. CLARKE:

One more if I might, your Honor.

301 THE COURT:

Uno mas.

302 MR. CLARKE:

Protocols that you have described previously as being used in your own laboratory, do you always follow or do your technicians always follow those protocols exactly?

303 DR. GERDES:

In any laboratory you have the protocol is followed as carefully as possible and as exactly as possible. If there is any situation that occurs where that can't be the case, then the technician is instructed to direct--to ask the director whether or not a change is--changes can be made and which changes can or can't be made.

304 MR. CLARKE:

Thank you, your Honor.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
This is gross contamination.
Gerdes' own characterization of the People's 568 photograph, which Clarke then used to show that LAPD's negative controls caught and flagged the problem — turning Gerdes' damaging language into a point for the prosecution.
Dr. John Gerdes
It should be totally clean. There should be nothing there.
Gerdes describing what a negative control should show, moments before Clarke establishes that the LAPD analyst correctly identified the contaminated run and noted it.
George Clarke
It is correct that the control worked in this instance revealing contamination, correct, Dr. Gerdes?
The pivot of the entire exchange — Clarke used Gerdes' own 'gross contamination' finding to demonstrate that LAPD's quality controls functioned as intended.
Dr. John Gerdes
If you've ever seen Gary Sims' notes, they are extremely detailed. All you have to do is read the notes.
Gerdes defending his decision not to question analysts directly, while inadvertently complimenting DOJ analyst Gary Sims — a prosecution witness.
Lance A. Ito
Uno mas.
The judge's casual Spanish for 'one more' when Clarke asked for a final question — a small levity in an otherwise technical proceeding.

Evidence (2)

People's 568
Photograph of LAPD hybridization record 101, run January 14, 1994 by analyst Erin Riley (confirmed by Collin Yamauchi), showing multiple alleles in the negative control — a gross contamination event that the analyst detected and noted
Introduced and displayed; used by Clarke to demonstrate LAPD quality controls successfully caught contamination
Defense 1297
Gerdes' chart showing strip and run contamination percentages for May, June, and July 1994 at LAPD, with bars approximating 33%, 31%, and 17% respectively
Referenced and challenged; Clarke argued the figures overstated contamination by including 1.1 and 1.3 alleles attributable to cross-hybridization

Notable Exchanges (3)

George ClarkeDr. John Gerdes
Clarke methodically walked through Gerdes' contamination charts for May, June, and July, extracting admissions that each percentage included 1.1 and 1.3 alleles that might be cross-hybridization artifacts rather than contamination, building to the conclusion that the charts overstate LAPD contamination.
strategic
George ClarkeDr. John Gerdes
Clarke introduced People's 568 showing a January 1994 run with gross contamination, drew out Gerdes' damning description of it, then flipped the narrative by confirming the analyst detected, noted, and presumably rejected the contaminated run — suggesting LAPD's controls worked.
revealing
George ClarkeDr. John Gerdes
Clarke probed why Gerdes never contacted any analysts with questions despite reviewing vast amounts of material from multiple labs. Gerdes defended himself by citing Gary Sims' detailed notes and familiarity with Cellmark and DOJ protocols from prior cases.
strategic

Light Moments (2)

Lance A. Ito
Judge Ito responded to Clarke's request for 'one more' question with 'Uno mas.'
Lance A. Ito
Ito interrupted the witness examination to tell Gerdes, who had stepped down to view a chart: 'Would you take a half step back. You are shielding the court reporter.'

Credibility Attacks (3)

⚔ Dr. John Gerdes
Methodological bias / chart accuracy
Clarke established that Gerdes' contamination charts for May, June, and July included 1.1 and 1.3 alleles that Gerdes himself acknowledged could be cross-hybridization rather than contamination, meaning the charts overstated LAPD contamination rates — potentially by up to 16 percent per Gerdes' own estimate.
⚔ Dr. John Gerdes
Insufficient basis for opinion
Clarke challenged Gerdes' failure to contact any of the DNA analysts with questions despite reviewing mountains of material, suggesting his conclusions rested on an incomplete foundation. Gerdes defended the sufficiency of written records and his prior familiarity with the labs.
⚔ Dr. John Gerdes
Imprecise terminology
Clarke exposed that Gerdes had called his lab visits 'site visits,' a term with a specific formal meaning involving authorized accreditation inspections. Gerdes conceded it was 'a misnomer' and that he had no authority of any accrediting agency.

Witness Demeanor

(Witness complies.) — stepping down to view chart at Clarke's request
(Witness complies.) — returning to the stand
Gerdes repeatedly asked to explain his methodology but was cut off by Ito, who deferred explanation to redirect
Gerdes asked to consult his notes mid-answer regarding allele percentage calculations

Objections

6 objections (3 sustained, 3 overruled)
Proceeding 7174 • 304 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 4, 1995 📄 Cross-examination of Dr. John
AUG 4, 1995 KRT DvH TD